MedKoo Cat#: 527473 | Name: MO-I-500
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MO-I-500 is a FTO inhibitor (IC50 = 8.7 μM for purified FTO in vitro), which increases N6-methyladenosine (m6A) levels in total cellular mRNA in HeLa cells. MO-I-500 modulates levels of specific miRNAs. In a triple-negative breast cancer cell line metabolically challenged by culture without glutamine (SUM149-MA cells), MO-I-500 inhibits cell proliferation. MO-I-500 also displays anticonvulsant activity in a 6 Hz mouse model of epilepsy at nontoxic doses.

Chemical Structure

MO-I-500
CAS#1585219-04-0

Theoretical Analysis

MedKoo Cat#: 527473

Name: MO-I-500

CAS#: 1585219-04-0

Chemical Formula: C12H12ClNO5S

Exact Mass: 317.0125

Molecular Weight: 317.74

Elemental Analysis: C, 45.36; H, 3.81; Cl, 11.16; N, 4.41; O, 25.18; S, 10.09

Price and Availability

Size Price Availability Quantity
10mg USD 370.00 2 Weeks
50mg USD 1,090.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MO-I-500; MOI-500; MO I-500; MO-I500; MO-I 500; MO I 500; MOI500;
IUPAC/Chemical Name
N-(3,4-Dihydroxy-5-(4-chlorophenyl)-2-furanyl)ethanesulfonamide
InChi Key
WWHUSZQHRUNRSB-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H12ClNO5S/c1-2-20(17,18)14-12-10(16)9(15)11(19-12)7-3-5-8(13)6-4-7/h3-6,14-16H,2H2,1H3
SMILES Code
CCS(=O)(NC1=C(O)C(O)=C(C2=CC=C(Cl)C=C2)O1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM.
In vitro activity:
MO-I-500, a pharmacological inhibitor of FTO, significantly (>90%) inhibited survival and/or colony formation of SUM149-MA cells as compared to untreated cells or those treated with a control compound MO-I-100. Curiously, MO-I-500 treatment also led to decreased levels of FTO and IRX3 proteins in the SUM149 cells initially surviving in glutamine-free medium as compared to MO-I-100 treatment. Reference: PLoS One. 2016 Jul 8;11(7):e0159072. https://pubmed.ncbi.nlm.nih.gov/27390851/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMSO 31.8 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 317.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. PMID: 27390851; PMCID: PMC4938613.
In vitro protocol:
Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. PMID: 27390851; PMCID: PMC4938613.
In vivo protocol:
TBD
1: Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. PMID: 27390851; PMCID: PMC4938613.